Viatris Inc. (VTRS)
| Market Cap | 19.14B +60.3% |
| Revenue (ttm) | 14.74B +4.4% |
| Net Income | -410.70M |
| EPS | -0.35 |
| Shares Out | 1.15B |
| PE Ratio | n/a |
| Forward PE | 6.55 |
| Dividend | $0.48 (2.88%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 7,027,353 |
| Open | 16.64 |
| Previous Close | 16.51 |
| Day's Range | 16.47 - 16.85 |
| 52-Week Range | 9.43 - 18.39 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 18.67 (+12.07%) |
| Earnings Date | Aug 6, 2026 |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for VTRS stock is "Buy." The 12-month stock price target is $18.67, which is an increase of 12.07% from the latest price.
News
Leerink sees growth for Viatris, starts at Outperform
As previously reported, Leerink analyst Daniel Clark initiated coverage of Viatris (VTRS) with an Outperform rating and $20 price target The firm expects revenue and EBITDA growth in 2026 after…
Viatris initiated with an Outperform at Leerink
Leerink initiated coverage of Viatris (VTRS) with an Outperform rating and $20 price target
Viatris price target raised to $20 from $15 at Argus
Argus raised the firm’s price target on Viatris (VTRS) to $20 from $15 and keeps a Buy rating on the shares. The company’s favorable growth strategy is supported by a…
Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M
Harrow (HROW) announced that it has entered into a definitive agreement to acquire Tyrvaya nasal spray 0.03 mg from Viatris (VTRS). Tyrvaya is a cholinergic agonist indicated for the treatment…
Viatris Earnings Call Transcript: Q2 2026
Q2 revenues grew 3.5% year-over-year to $3.8 billion, with strong performance in Greater China and North America driving a guidance raise for all key 2026 metrics. Pipeline progress, cost savings, and capital returns support long-term growth, despite supply and policy headwinds.
Viatris Slides: Q2 2026
Viatris has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Viatris Earnings release: Q2 2026
Viatris released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Viatris Quarterly report: Q2 2026
Viatris has published its Q2 2026 quarterly earnings report on August 6, 2026.
Viatris reports Q2 adjusted EPS 69c, consensus 60c
Reports Q2 revenue $3.76B, consensus $3.67B. “Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we’re building across our business,” said Scott A. Smith...
Viatris raises FY26 adjusted EPS view to $2.45-$2.59 from $2.33-$2.47
Consensus $2.45. Narrows FY26 revenue view to $14.55B-$14.95B from $14.45B-$14.95B, consensus $14.78B. Raises FY26 adjusted EBITDA view to $4.3B-$4.5B from $4.15B-$4.45B. “We delivered another strong ...
Viatris Reports Second-Quarter 2026 Financial Results
Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to ...
Viatris Announces Quarterly Dividend
PITTSBURGH, Aug. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and...
Viatris receives FDA approval for Gwyn Lo contraceptive patch
Viatris (VTRS) announced that the FDA has approved Gwyn Lo, a new combined hormonal contraceptive patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbear...
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option Approval Marks an Important Milestone in Viatris' Efforts to Advance Women's Health PITTSBURGH, July 29, 2026 /PRNewswir...
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for brande...
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows
Mylan Inc plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd , worth up to 34.81 billion Indian rupees ($363 million), according to a term sheet seen by Reuters.
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Com...
Viatris announces VR-205 trial achieves primary endpoint
Viatris (VTRS) announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 in Japanese adult patients with primary immunoglobulin A nephropathy at risk of…
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies Japan...
Viatris price target raised to $22 from $17 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on Viatris (VTRS) to $22 from $17 and keeps an Overweight rating on the shares. The company reported “strong” Q1 results…
Viatris says FDA accepts for review NDA for MR-107A-02
Viatris (VTRS) announced that the U.S. FDA has accepted for review the New Drug Application for MR-107A-02, a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned…
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration ...
Viatris Transcript: Bank of America Global Healthcare Conference 2026
North America growth is driven by generics and complex launches, with cost savings and strong free cash flow supporting flexibility. Key pipeline launches in Japan and North America, including meloxicam and selatogrel, are expected to accelerate growth, diversify revenue, and extend exclusivity.
Viatris price target raised to $20 from $18 at Truist
Truist raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Buy rating on the shares. The company’s Q1 results featuring a 5% revenue beat…
Viatris price target raised to $18 from $17 at JPMorgan
JPMorgan raised the firm’s price target on Viatris (VTRS) to $18 from $17 and keeps a Neutral rating on the shares.